European consensus proposal for immunoglobulin therapies


  • W. A. Carrock Sewell,

    1. University of Lincoln & Hull York Medical School, UK
    Search for more papers by this author
  • Jacqueline Kerr,

    1. Paul-Ehrlich Institute, Langen, Germany
    Search for more papers by this author
  • Marie-Emmanuelle Behr-Gross,

    1. EDQM, Council of Europe, Strasbourg, France
    Search for more papers by this author
  • Hans-Hartmut Peter,

    1. Centre for Chronic Immunodeficiency (CCI), Freiburg, Germany
    Search for more papers by this author
  • on behalf of the Kreuth Ig Working Group

    1. Members of the Kreuth Ig-Working Group (WG): Marie-Emmanuelle Behr-Gross, EDQM, Strasbourg, France Jose Drabwell, Chair IPOPI Board, England, UK Martha Eibl, Immunologische Tagesklinik, Vienna, Austria Basil Golding, Associate Director for Medical Affairs, US Food and Drug Administration, Silver Spring, MD, USA Jacqueline Kerr, Paul Ehrlich Institute, Langen, Germany Taco Kuijpers, Department of Pediatric Hematology, Immunology & Infectious disease, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands Hans-Hartmut Peter, Centre for Chronic Immunodeficiency, Freiburg, Germany Isabella Quinti, Department of Immunology, Sapienza, Roma Ivo N. van Schaik, Department of Neurology, AMC, University of Amsterdam, Amsterdam, Netherlands Anna Sediva, University Hospital Motol, Prague, Czech Republic W A Carrock Sewell, University of Lincoln & Hull York Medical School, UK Mikko Seppänen, University Central Hospital, Helsinki, Finland Peter J. Späth, Lecturer em., Institute of Pharmacology, University of Berne, Berne, Switzerland
    Search for more papers by this author

  • Results from the Wildbad Kreuth III Meeting on “Optimal use of clotting factors and immunoglobulins” organized by the European Directorate for the Quality of Medicines & Health Care, Strasbourg, France, the Paul Ehrlich Institute, Langen Germany and the Ludwig Maximillian University Munich, Germany. April 26–27, 2013.

  • Organizers and Scientific Program Committee: Prof. R. Seitz, Dr. M.-E. Behr-Gross, Dr. K.-H. Bucheit, Prof. W. Schramm, Ms. K. Berger, Dr. A. Hilger, Dr. J. Kerr, Prof. H.-H. Peter.

  • This consensus proposal is aiming at encouraging comments and letters to build a discussion platform for a future consensus statement.

Full correspondence Prof. Hans-Hartmut Peter, Centre for Chronic Immunodeficiency (CCI), Engesserstr.4, D-79108 Freiburg, Germany

Fax: +49-761-27078121



The use of immunoglobulin (Ig) preparations (intravenous, IVIg, subcutaneous, SCIg) for replacement and immunomodulation therapy worldwide has tripled in the past 20 years and represents an ever-increasing cost factor for healthcare organizations. The limited access to the starting material of this essential medicinal product is currently the driving force for human plasma collection. Increasing awareness and improved diagnosis of human primary immunodeficiencies and a broadening of immunomodulatory indications are responsible for this development, and on a longer run might lead to plasma supply shortages. Consensus recommendations for the optimal use of Ig in clinical practice, including priority rankings for the most urgent indications, are therefore urgently needed. During a recent meeting in Kreuth, Germany, expert nominees from 36 Council of Europe states, together with colleagues from observer countries and regulatory agencies came up with this consensus statement.